biosynthetic convalescent plasma

Biosynthetic convalescent plasma is an investigational **antibody cocktail biologic** developed by Immunome for treatment of COVID-19. It was described as a synthetically manufactured combination of approximately 4 to 6 highly potent anti-SARS-CoV-2 antibodies identified from B cells of patients who recovered from COVID-19 infection. The intended mechanism is to bind SARS-CoV-2 and provide broad viral neutralization and multiple viral clearance mechanisms while avoiding limitations of donor-derived convalescent plasma such as supply constraints, donor variability, and poor scalability. The program appears to have been positioned as an industrially scalable, standardized alternative to traditional convalescent plasma.

Other names

biosynthetic convalescent plasmaBCP